sales@reportocean.com (Bussiness Sales)
+18882123539 (Us - Toll Free)
+919997112116 (Rest Of World)
Global Insulin Market - Focus on Insulin Delivery Devices Market Outlook 2022

Global Insulin Market - Focus on Insulin Delivery Devices Market...

Home / Categories / Healthcare
Global Insulin Market - Focus on Insulin Delivery Devices Market Outlook 2022
Global Insulin Market - Focus...
Report Code
RO1/119/1007

Publish Date
02/Mar/2017

Pages
105
PRICE
$ 1800/-
This is a single user license, allowing one specific user access to the product. The product is a PDF.
$ 2350/-
This is a 1-5 user license, allowing up to five users have access to the product. The product is a PDF.
$ 2850/-
This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF..
1. Executive Summary
2. Research Methodology
3. Introduction
4. Diabetes
4.1.1 Overview
4.1.2 Cost - Human & Financial
5. Insulin Market
5.1 Overview
5.2 Market Analysis
5.2.1 Market Sizing (Actual & Forecasted)
5.2.2 Market Share by Insulin Type
5.2.3 Market Share by Segment
5.2.4 Market Share by Region
6. Insulin Delivery Devices
6.1 Overview
6.2 Vial and syringe
6.2.1 Overview
6.2.2 Market Sizing (Actual & Forecasted)
6.3 Insulin pen
6.3.1 Overview
6.3.2 Market Sizing (Actual & Forecasted)
6.4 Insulin Pump
6.4.1Overview
6.4.1 Market Sizing (Actual & Forecasted)
6.5 Others
6.6 Market Share Analysis
6.6.1 Market Share by Devices
6.6.2 Market Share by End-User
6.6.3 Market Share by Region
7. Regional/ Country Analysis
7.1 Europe
7.1.1 Overview
7.1.2 Market Sizing (Actual & Forecasted)
7.1.3 Market Share
7.2 North America and Caribbean
7.2.1 Overview
7.2.2 Market Sizing (Actual & Forecasted)
7.2.3 Market Share
7.4 China
7.4.1 Overview
7.4.2 Market Sizing (Actual & Forecasted)
7.4.3 Market Share
8. Pricing Analysis
9. Global Insulin Market Dynamics
9.1 Industry Trends & Developments
9.1.1 Dominance of Modern and New-Generation Insulin
9.1.2 Advent of Intelligent Insulin Pens
9.1.3 Sensor-augmented Pump Therapy
9.1.4 Approval of Glargine Basaglar - The First ?Biosimilar? Insulin in the US
9.3 Growth Drivers
9.3.1 Increasing Prevelance of Diabetes
9.3.2 Rise in Geriatric Population
9.3.3 Growing Obese Population
9.3.4 Propogation of Diabetes Management Awareness
9.3.5 Government Impetus
9.4 Challenges
9.4.1 High Cost of Insulin
9.4.2 Insurance Coverage issue
9.4.3 High Competition
9.4.4 Regulatory Pressure
10. Competitive Landscape
10.1 Market Share by Competitors
10.2 Market Share by Drug Brands
11. Company Profiles
11.1 Novo Nordisk
11.2 Sanofi Aventis
11.3 Eli Lilly and Company
11.4 Merck & Co.

OUR CLIENTS

500 N Michigan Ave, Suite 600, Chicago, Illinois 60611, UNITED STATES
+18882123539
sales@reportocean.com